vs
Side-by-side financial comparison of First Foundation Inc. (FFWM) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $48.4M, roughly 1.2× First Foundation Inc.). RHYTHM PHARMACEUTICALS, INC. runs the higher net margin — -83.0% vs -97.9%, a 14.9% gap on every dollar of revenue. On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs 36.9%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -2.7%).
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
FFWM vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $57.3M |
| Net Profit | $-8.0M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | -97.5% | -82.2% |
| Net Margin | -97.9% | -83.0% |
| Revenue YoY | 421.7% | 36.9% |
| Net Profit YoY | 43.0% | -9.6% |
| EPS (diluted) | $-0.09 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $57.3M | ||
| Q3 25 | $63.6M | $51.3M | ||
| Q2 25 | $51.4M | $48.5M | ||
| Q1 25 | $71.4M | $32.7M | ||
| Q4 24 | $9.3M | $41.8M | ||
| Q3 24 | $9.2M | $33.3M | ||
| Q2 24 | $57.5M | $29.1M | ||
| Q1 24 | $51.1M | $26.0M |
| Q4 25 | $-8.0M | $-47.5M | ||
| Q3 25 | $-146.3M | $-52.9M | ||
| Q2 25 | $-7.7M | $-46.6M | ||
| Q1 25 | $6.9M | $-49.5M | ||
| Q4 24 | $-14.1M | $-43.3M | ||
| Q3 24 | $-82.2M | $-43.6M | ||
| Q2 24 | $3.1M | $-32.3M | ||
| Q1 24 | $793.0K | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | -97.5% | -82.2% | ||
| Q3 25 | -92.7% | -102.6% | ||
| Q2 25 | -21.1% | -93.4% | ||
| Q1 25 | 8.8% | -143.7% | ||
| Q4 24 | -247.7% | -98.6% | ||
| Q3 24 | -1276.7% | -132.0% | ||
| Q2 24 | 4.6% | -139.2% | ||
| Q1 24 | -0.2% | -538.7% |
| Q4 25 | -97.9% | -83.0% | ||
| Q3 25 | -230.1% | -103.1% | ||
| Q2 25 | -15.0% | -96.1% | ||
| Q1 25 | 9.7% | -151.4% | ||
| Q4 24 | -152.2% | -103.6% | ||
| Q3 24 | -896.9% | -131.2% | ||
| Q2 24 | 5.4% | -110.9% | ||
| Q1 24 | 1.6% | -544.4% |
| Q4 25 | $-0.09 | $-0.73 | ||
| Q3 25 | $-1.78 | $-0.82 | ||
| Q2 25 | $-0.09 | $-0.75 | ||
| Q1 25 | $0.08 | $-0.81 | ||
| Q4 24 | $-0.24 | $-0.71 | ||
| Q3 24 | $-1.23 | $-0.73 | ||
| Q2 24 | $0.05 | $-0.55 | ||
| Q1 24 | $0.01 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $912.6M | $139.1M |
| Total Assets | $11.9B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $388.9M | ||
| Q3 25 | $1.7B | $416.1M | ||
| Q2 25 | $1.1B | $291.0M | ||
| Q1 25 | $1.0B | $314.5M | ||
| Q4 24 | $1.0B | $320.6M | ||
| Q3 24 | $1.1B | $298.4M | ||
| Q2 24 | $1.4B | $319.1M | ||
| Q1 24 | $1.6B | $201.2M |
| Q4 25 | $912.6M | $139.1M | ||
| Q3 25 | $917.9M | $148.8M | ||
| Q2 25 | $1.1B | $-11.9M | ||
| Q1 25 | $1.1B | $18.9M | ||
| Q4 24 | $1.1B | $21.7M | ||
| Q3 24 | $1.1B | $11.2M | ||
| Q2 24 | $933.2M | $39.3M | ||
| Q1 24 | $928.7M | $61.6M |
| Q4 25 | $11.9B | $480.2M | ||
| Q3 25 | $11.9B | $506.9M | ||
| Q2 25 | $11.6B | $372.7M | ||
| Q1 25 | $12.6B | $386.7M | ||
| Q4 24 | $12.6B | $392.3M | ||
| Q3 24 | $13.4B | $363.6M | ||
| Q2 24 | $13.7B | $381.8M | ||
| Q1 24 | $13.6B | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.9M | $-25.4M |
| Free Cash FlowOCF − Capex | $-35.2M | — |
| FCF MarginFCF / Revenue | -72.8% | — |
| Capex IntensityCapex / Revenue | 6.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-45.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.9M | $-25.4M | ||
| Q3 25 | $9.2M | $-26.6M | ||
| Q2 25 | $-16.3M | $-23.3M | ||
| Q1 25 | $-552.0K | $-40.4M | ||
| Q4 24 | $-8.7M | $-18.8M | ||
| Q3 24 | $14.2M | $-25.2M | ||
| Q2 24 | $-9.1M | $-29.1M | ||
| Q1 24 | $7.2M | $-40.7M |
| Q4 25 | $-35.2M | — | ||
| Q3 25 | $8.6M | — | ||
| Q2 25 | $-16.7M | — | ||
| Q1 25 | $-2.5M | — | ||
| Q4 24 | $-11.4M | — | ||
| Q3 24 | $13.4M | — | ||
| Q2 24 | $-9.4M | — | ||
| Q1 24 | $5.9M | — |
| Q4 25 | -72.8% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | -32.4% | — | ||
| Q1 25 | -3.5% | — | ||
| Q4 24 | -123.5% | — | ||
| Q3 24 | 146.2% | — | ||
| Q2 24 | -16.3% | — | ||
| Q1 24 | 11.6% | — |
| Q4 25 | 6.9% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 9.0% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.08× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.96× | — | ||
| Q1 24 | 9.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
